Insmed stock

INSM · NASDAQ · USD

Compare Insmed
$121.16Change from previous close: +2.62%Absolute change: +$3.09

Close · November 13, 2026

Price history

−36.55% over the period

1 year: from $190.96 (November 13, 2025) to $121.16 (November 13, 2026), −36.55%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026$121.16
October 30, 2026$112.58
September 30, 2026$114.14
August 31, 2026$121.82
July 31, 2026$98.60
June 30, 2026$106.62
May 29, 2026$106.91
April 30, 2026$136.33
March 31, 2026$163.52
February 27, 2026$149.33
January 30, 2026$156.87
December 31, 2025$174.04
November 28, 2025$207.77
November 13, 2025$190.96

At a glance

  • The company

    Develops and commercializes therapies for serious and rare diseases, including ARIKAYCE for lung infections

  • Latest results

    Quarter to September 30, 2026 · EPS -$0.46 (estimate -$0.39)

TickerLandia's take on Insmed

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$90.39
52-wk high$212.75

−43.05% from the 52-week high

Analysts · 24 analysts

Average target$194.18+60.27% vs. price

Buy 23 · Hold 1 · Sell 0 · Strong buy

TickerLandia Fingerprint: Insmed

Compared with similar companies: very high price and very low financial strength.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Insmed is pricier than similar companies

Insmed's Forward P/E: 184.1, +1,108% against the median of a group of 7 similar companies (15.2).

Compared with 7 similar companies

Insmed's metrics compared with similar companies
MetricInsmedPosition in the groupBand
Forward P/E184.1High
Operating margin-41.7%Middle
ROE-72.5%Low
Debt/equity1.01High
Price/book36.6High

Grey band: the middle half of the group; tick: the median; dot: Insmed. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$425.49M

Latest quarter · Q2 2026

Net income

-$13.24M

Latest quarter · Q2 2026

Quarterly net margin

-3.1%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$26.58B
EPS
-$2.88
Volume
1.54M
Daily trading
€362.35M
Dividend yield
0.00%

How Insmed is changing

All results
  • Revenue grew 29.8% a year on average over the last 5 years

  • Operating margin fell from −186.4% to −205.6%

  • Shares outstanding up 103.9% in 5 years

Returns

Insmed returns

$1,000 invested in Insmed 5 years ago, on November 15, 2021, would be worth $3,972 today: +297.25% in total, +31.81% per year. This is the price return only: dividends are excluded.

PeriodInsmedS&P 500$1,000 becomes
1 month+25.18%−3.12%$1,252
6 months+2.69%+1.58%$1,027
Year to date−30.38%+10.46%$696
1 year−36.55%+12.23%$634
3 years+406.95%+71.41%$5,069
5 years+297.25%+61.48%$3,972
10 years+701.85%+249.40%$8,019

Over the last 6 months it has done better than 28% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Insmed: technical analysis

Insmed shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 84.1% below its all-time closing high ($760.00, December 30, 1991).

Trend
No clear trend
RSI (14 sessions)
65
Between 30 and 70
vs 200-session average
−1.63%

Active signals

  • Close above the high of the previous 20 sessions.

Support and resistance

Price areas where Insmed has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$166.34+37.29%3 touches, last on April 6, 2026
  2. Resistance$142.95+17.98%2 touches, last on May 5, 2026
  3. Resistance$136.39+12.57%3 touches, last on August 6, 2026
  4. Last price$121.16
  5. Support$117.85−2.73%4 touches, last on October 30, 2026
  6. Support$91.51−24.47%2 touches, last on October 23, 2026

Volatility and risk

Over the last year it has moved less than the S&P 500.

Beta (1 year) vs S&P 500
0.56
Volatility (60 sessions, annualised)
48.8%
Largest fall in the last year
−56.54%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Insmed: seasonality

Average monthly price change over 36 years

+6.9%Jan+7.3%Feb−4.9%Mar+4.2%Apr+5.8%May+2.8%Jun−0.2%Jul−1.2%Aug+3.2%Sep−1.4%Oct+10.4%Nov+3.9%Dec

Over the last 36 years, the strongest month for Insmed has been November: +10.43% on average, positive in 23 years out of 35. The weakest has been March: −4.85% on average, positive in 14 years out of 36.

Show chart data
MonthAverageMedianPositive years
January+6.93%−0.06%16 of 35
February+7.27%−2.37%14 of 35
March−4.85%−3.48%14 of 36
April+4.24%−3.08%14 of 36
May+5.82%−2.65%14 of 36
June+2.77%+4.06%19 of 36
July−0.18%−1.72%17 of 36
August−1.22%−2.52%16 of 36
September+3.16%+1.59%19 of 36
October−1.42%−1.06%16 of 36
November+10.43%+9.58%23 of 35
December+3.86%−0.03%16 of 35

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Insmed and its competitors

Founded in 1988 and headquartered in Bridgewater, New Jersey, Insmed Incorporated works on treatments for adults with lung conditions and for rare genetic disorders. Its ARIKAYCE product is offered for refractory nontuberculous mycobacterial lung infections, and several candidates are in clinical trials. Brensocatib, an oral DPP1 inhibitor, is in phase 3 testing for bronchiectasis and in phase 2 for chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa.

Headquarters
Bridgewater, United States
Employees
1,664
Founded
1988
Chief executive
William Lewis
Insmed and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
InsmedINSM$26.58B-41.7%—+2.69%
IncyteINCY$24.66B32.2%61.7+22.41%
Roivant SciencesROIV$28.64B-3,226.3%—+35.28%
Alnylam PharmaceuticalsALNY$22.11B19.5%8.34−43.38%
BioNTechBNTX$21.22B-55.4%—−7.19%
Revolution MedicinesRVMD$37.27B-853.0%—+14.91%

Same industry or related industries, similar size. Compare Insmed with its competitors · Full profile